Lottie Moss and GLP-1 regret: separating the story from the science

What did @risewithroxie actually say?

The video recounts Lottie Moss's personal experience with semaglutide (she calls it "exam pick," clearly meaning Ozempic). Her core claim is specific and worth taking seriously: she was prescribed a dose "for someone who's double the size of me" by a doctor who skipped basic intake checks like blood pressure, and the result was a trip to A&E with severe, unrelenting vomiting and an inability to keep down any food or fluids. This isn't a vague wellness complaint. It's an account of what sounds like serious semaglutide-induced gastrointestinal toxicity from a dose mismatch.

The story is told in first person and framed as a cautionary tale. There's no sensationalism about the drug being inherently dangerous, just a clear narrative about what happens when prescribing standards slip. That framing actually matters, because it's more honest than a lot of GLP-1 content circulating on TikTok right now.

Does the science back this up?

Yes, substantially. Dose-dependent gastrointestinal side effects are the most well-documented adverse events associated with semaglutide. The SUSTAIN and STEP trial series consistently showed nausea and vomiting as the leading reasons for discontinuation, and these effects scale with dose escalation. What Moss describes, being unable to hold down "no water, no liquids, no food," is consistent with what clinicians call semaglutide-induced gastroparesis or severe GI intolerance, particularly when dose titration is skipped.

A 2022 paper by Nauck et al. in Nature Reviews Drug Discovery documented that inappropriate dose escalation is a primary driver of adverse GI events with GLP-1 receptor agonists. A 2023 pharmacovigilance study by Sodhi et al. in JAMA further flagged that GI complications, including hospitalization-level events, are meaningfully more common when titration protocols aren't followed. The A&E visit she describes is plausible and medically coherent, not exaggerated.

What did they get wrong (or right)?

Credit where it's due: the core account is credible. The link between overdosing on semaglutide and severe vomiting is real, and her description of inadequate clinical oversight, no blood pressure check, no proper intake, is a genuine problem in the unregulated end of the weight-loss injection market.

What's less clear is causality framing. Moss implies the dose given was flat-out wrong for her body size, which is partially right. Semaglutide dosing isn't strictly weight-based in the way she implies, it follows a fixed titration schedule starting at 0.25mg weekly regardless of body size. The bigger clinical error she's describing is likely skipping titration entirely, not necessarily giving a "double the size" dose in the way she frames it. That distinction matters because it shifts the risk factor from body weight to prescribing negligence specifically around titration, which is the more accurate lesson here.

She doesn't make any false claims about the drug being universally dangerous or ineffective. That restraint is notable given the platform.

What should you actually know?

Semaglutide has a mandatory slow titration protocol for a reason. The standard starting dose is 0.25mg weekly for four weeks before any increase, and this exists specifically to reduce GI adverse events. Any prescriber skipping this, or skipping baseline health checks, is operating outside clinical guidelines. The UK's MHRA and NICE both require clinical assessment before initiation, including cardiovascular history, which blood pressure screening is part of.

The broader context here is the explosion of online and clinic-based GLP-1 prescribing with minimal oversight. A 2023 report from the Care Quality Commission flagged exactly this pattern: rapid prescribing without adequate patient assessment in weight-loss clinics. Moss's experience, if accurate, fits that pattern precisely. Regulated telehealth platforms are required to conduct clinical intake, review contraindications, and follow dose escalation protocols. If a provider skipped all of that, the issue is the provider, not the drug class itself.

If you experience persistent vomiting, inability to keep fluids down, or severe nausea after starting a GLP-1 medication, stop the medication and seek medical attention. These are not symptoms to push through.